Literature DB >> 1583082

Metformin and blood pressure.

K Landin-Wilhelmsen1.   

Abstract

Hypertension appears to predispose to both atheroma and thrombus formation and is a risk factor for stroke and coronary artery disease. Insulin resistance and hyperinsulinaemia are also associated with hypertension, whether treated or untreated and irrespective of obesity. In an attempt to treat the possible insulin resistance in hypertension, an antidiabetic agent, metformin, which enhances glucose uptake, was given to non-obese, non-diabetic, untreated hypertensives in a pilot study. Metformin improved insulin sensitivity, decreased plasma insulin, serum cholesterol and triglycerides, increased fibrinolytic activity and markedly decreased blood pressure. These findings support the concept that insulin resistance may be important in cases of primary hypertension, i.e. those with concomitant metabolic and possibly also fibrinolytic abnormalities. Furthermore, the results indicate that insulin resistance may precede hypertension in these cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583082     DOI: 10.1111/j.1365-2710.1992.tb01271.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  9 in total

1.  Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial.

Authors:  Mateus Dornelles Severo; Thais Stürmer Andrade; Vicente Correa Junior; Alexandre Antonio Naujorks; Miguel Gus; Beatriz D Schaan
Journal:  Endocrine       Date:  2017-10-27       Impact factor: 3.633

2.  Metformin prevents the impairment of endothelium-dependent vascular relaxation induced by high glucose challenge in rabbit isolated perfused kidneys.

Authors:  M B Gomes; S Cailleaux; E Tibiriçá
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-26       Impact factor: 3.000

3.  Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo.

Authors:  Quanlu Duan; Ping Song; Ye Ding; Ming-Hui Zou
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

Review 4.  Metformin therapy in diabetes: the role of cardioprotection.

Authors:  Saloua El Messaoudi; Gerard A Rongen; Niels P Riksen
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

5.  Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Authors:  Jacob D Peuler; Laura E Phelps
Journal:  J Smooth Muscle Res       Date:  2015

Review 6.  Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors.

Authors:  Cosmin Mihai Vesa; Loredana Popa; Amorin Remus Popa; Marius Rus; Andreea Atena Zaha; Simona Bungau; Delia Mirela Tit; Raluca Anca Corb Aron; Dana Carmen Zaha
Journal:  Diagnostics (Basel)       Date:  2020-05-16

Review 7.  The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.

Authors:  Józef Drzewoski; Markolf Hanefeld
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-05

8.  Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin.

Authors:  Mahdi Hamidi Shishavan; Robert H Henning; Azuwerus van Buiten; Maaike Goris; Leo E Deelman; Hendrik Buikema
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

Review 9.  Effects of metformin on endothelial health and erectile dysfunction.

Authors:  Jay Pravin Patel; Eric Hweegeun Lee; Carlos Ignacio Mena; Charles N Walker
Journal:  Transl Androl Urol       Date:  2017-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.